The company said that an epilepsy medication is a natural extension to its product line.
The prevalence of migraine in people who experience epilepsy is 8.4 to 20%, according to an article in Seizure.
PuraMed BioScience chairman and CEO Russell Mitchell said as the company looked at the similarities between migraine and epilepsy the treatment path became obvious.
"Epilepsy and migraine seem to be triggered by the same coritcal spreading depression (CSD) in the brain; the difference is the rate of reaction. This may be why many migraineurs are prescribed epileptic medications," Mitchell said.
Besides migraine, an estimated 64% of epilepsy sufferers also experience seizure-related (ictal) headaches: 20% experience headache prior to the seizure (pre-ictal) and 44% experience headache after the seizure (post-ictal).
In the US, epilepsy is the third most common neurological disorder, which affects about 2.7 million people, with children and older adults being most susceptible.
Mitchell said: "We have developed a formula, now we will begin the setting up the trials. We have been approached by key researchers who have expressed interest in working with us on CBD-based products.
"Standardization is key to creating a quality sublingual formula.
"Sublingual delivery offers the distinct advantages of faster delivery and efficiency while avoiding the "first pass effect" that often degrades oral medications.
"Our goal is to build medicines that withstand scientific scrutiny and perform well in double-blind, placebo controlled clinical trials. We believe that the efficacy of our formulations will be proven by scientific trials.
"This type of testing lends credibility to our line of natural medications which often work faster, more effectively, and have fewer side effects than their chemical-based counterparts."
Currently, the comapny is rebranding its product, LipiGesic M, as MigraPure.